NCT06995872 2026-04-15
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
Clinical Trials
34 trialsNCT00093353 2026-04-14
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT00509353 2026-04-14
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT05400603 2025-12-26
Aflac-NBL-2002
Emory University
Phase 1 Recruiting
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT07027748 2025-07-14
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT02975882 2025-01-14
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT04525014 2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1 Terminated
NCT03323034 2024-10-22
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Children's Oncology Group
Phase 1 Completed
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT00138216 2023-10-02
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT00876993 2023-07-03
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Johns Hopkins All Children's Hospital
Phase 1 Completed
NCT01528046 2023-01-13
Metformin in Children With Relapsed or Refractory Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01576692 2018-11-15
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00671801 2018-11-13
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00960063 2018-08-27
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00006025 2018-06-27
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00644696 2017-07-06
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01999270 2016-10-21
Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
Washington University School of Medicine
Phase 1 Completed
NCT00003484 2015-04-23
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1 Completed
NCT01518413 2015-02-27
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Children's National Research Institute
Phase 1 Completed
NCT00005951 2014-08-22
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Duke University
Phase 1 Completed
NCT00611728 2014-07-21
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Duke University
Phase 1 Completed
NCT02055196 2014-06-02
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Withdrawn
NCT00031681 2013-09-30
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Phase 1 Completed
NCT00762255 2013-07-25
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00002988 2013-06-20
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
Duke University
Phase 1 Completed
NCT00612638 2013-06-19
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Duke University
Phase 1 Completed
NCT00101270 2013-06-05
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003463 2013-02-18
Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas
Duke University
Phase 1 Completed
NCT00132158 2012-04-17
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00251797 2010-01-07
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
University of New Mexico
Phase 1 Completed